Charles Schwab Investment Management Inc. Boosts Holdings in Pulmonx Co. (NASDAQ:LUNG)

Charles Schwab Investment Management Inc. increased its holdings in Pulmonx Co. (NASDAQ:LUNG) by 0.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 315,532 shares of the company’s stock after purchasing an additional 2,363 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.80% of Pulmonx worth $2,142,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. FMR LLC boosted its position in Pulmonx by 11.2% in the 3rd quarter. FMR LLC now owns 5,872,882 shares of the company’s stock valued at $48,686,000 after buying an additional 591,859 shares during the period. PFM Health Sciences LP acquired a new position in shares of Pulmonx in the 3rd quarter valued at $3,058,000. Parkman Healthcare Partners LLC acquired a new stake in shares of Pulmonx in the third quarter worth $1,711,000. Polar Asset Management Partners Inc. acquired a new stake in Pulmonx during the third quarter worth about $893,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Pulmonx during the third quarter worth $480,000. 91.04% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Pulmonx news, Director Glendon E. French III sold 20,000 shares of the stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $7.85, for a total transaction of $157,000.00. Following the transaction, the director now directly owns 991,974 shares in the company, valued at $7,786,995.90. This represents a 1.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Geoffrey Beran Rose sold 5,779 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $7.13, for a total value of $41,204.27. Following the sale, the insider now directly owns 285,278 shares in the company, valued at approximately $2,034,032.14. This represents a 1.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 147,986 shares of company stock valued at $1,143,673. 5.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

LUNG has been the subject of several research analyst reports. Jefferies Financial Group initiated coverage on shares of Pulmonx in a research report on Monday, March 10th. They set a “buy” rating for the company. D. Boral Capital began coverage on Pulmonx in a research note on Monday, March 10th. They set a “buy” rating and a $17.00 target price on the stock. Wells Fargo & Company cut their target price on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 11th. Morgan Stanley initiated coverage on shares of Pulmonx in a research note on Monday, March 10th. They issued an “equal weight” rating on the stock. Finally, Citigroup began coverage on shares of Pulmonx in a research note on Monday, March 10th. They issued a “buy” rating on the stock. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Pulmonx currently has an average rating of “Moderate Buy” and an average target price of $13.36.

Pulmonx Stock Up 0.4 %

Pulmonx stock opened at $6.82 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70. The stock’s fifty day moving average is $7.17 and its two-hundred day moving average is $6.96. Pulmonx Co. has a fifty-two week low of $5.46 and a fifty-two week high of $10.01. The firm has a market capitalization of $271.41 million, a price-to-earnings ratio of -4.74 and a beta of 0.50.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings data on Wednesday, February 19th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12. The business had revenue of $23.77 million during the quarter, compared to the consensus estimate of $22.29 million. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. Analysts predict that Pulmonx Co. will post -1.55 EPS for the current fiscal year.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.